Drew Pardoll

Featured in: Favicon

nature.com Favicon

washingtonpost.com Favicon

science.org Favicon

healio.com Favicon

jimmunol.org Favicon

Articles

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses | Nature Medicine

Mar 19, 2024 | nature.com | Ronan Kelly |Blair V. Landon |Ali Zaidi |Nisha Rao |Kellie N. Smith |Drew Pardoll | +2 more

AbstractGastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy responses for these tumors.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →